1. Introduction {#sec1-diseases-04-00021}
===============

Research related to microRNAs (miRNAs) has gained prominence as a viable cancer therapy \[[@B1-diseases-04-00021]\]. These are short non-encoding RNAs of 20--24 nucleotides that are involved in gene regulation and cell signaling \[[@B2-diseases-04-00021]\].

They have been shown to contain gene-expression regulatory activities, and they can function both as promoters and inhibitors of oncogenesis \[[@B3-diseases-04-00021]\]. The inhibitory activities of miRNA have led researchers to investigate its potential in cancer therapeutics. MicroRNAs are known to achieve this inhibitory role by binding to *cis*-elements in the 3'-untranslated region (UTR) of mRNAs \[[@B4-diseases-04-00021]\]. Following the binding of miRNAs, inhibition occurs by one of three mechanisms: (1) target mRNA site-specific cleavage; (2) repression of target mRNA translation; and (3) mRNA degradation by cytoplasmic processing bodies \[[@B5-diseases-04-00021]\].

MicroRNAs are integral parts of feedback circuits in normal physiology. They play a role in cell differentiation, regulating cellular pathway and exhibiting buffering effects to key biological processes \[[@B2-diseases-04-00021],[@B6-diseases-04-00021],[@B7-diseases-04-00021],[@B8-diseases-04-00021],[@B9-diseases-04-00021],[@B10-diseases-04-00021],[@B11-diseases-04-00021],[@B12-diseases-04-00021]\]. On the other hand, deregulation of miRNA results in enhanced cellular plasticity, dedifferentiation and increased translation of oncogenes \[[@B13-diseases-04-00021],[@B14-diseases-04-00021],[@B15-diseases-04-00021]\].

Over 1400 human miRNAs have been identified, and many of these miRNAs are found to be strongly conserved across species \[[@B16-diseases-04-00021]\]. It is estimated that more than 60% of all mRNAs are regulated by miRNAs via posttrancriptional mode \[[@B17-diseases-04-00021]\]. It is for this reason that recent research has been directed towards understanding these miRNAs in diverse biological processes, including in a variety of diseases.

2. Biogenesis of miRNA {#sec2-diseases-04-00021}
======================

The canonical pathway of miRNA processing includes transcription by RNA polymerase II to form a primary miRNA (pri-miRNA) transcript with 5′-end caps and 3′-end poly-A tails ([Figure 1](#diseases-04-00021-f001){ref-type="fig"}). This transcript consists of more than one hairpin structure. It is subsequently cleaved by the nuclease, Drosha and its cofactor DiGeorge syndrome critical region 8 (DGCR8), thus generating a precursor miRNA (pre-miRNA). This pre-miRNA is transported from the nucleus to the cytoplasm by exportin-5 (Exp5) using RanGTP as a cofactor. It undergoes further processing in the cytoplasm by RNase III Dicer in a complex with trans-activation response RNA-binding protein (TRBP) to generate approximately 22-nucleotide duplex mature miRNA. Finally, the miRNA duplex unwinds and the functional strand of mature miRNA complexes with Argonaute (Ago2), forming an RNA-induced silencing complex (RISC). This RISC complex directs silencing via sequence-specific mRNAs target cleavage, translational repression and mRNA deadenylation \[[@B18-diseases-04-00021]\].

3. Mechanism of Action of miRNAs {#sec3-diseases-04-00021}
================================

The main mechanism with which miRNA effects protein-coding genes is by interaction with the 3′-UTR of target mRNA, subsequently leading to mRNA degradation or translation repression \[[@B19-diseases-04-00021]\]. The interaction of miRNA can also occur at the 5′-untranslated region (5′-UTR) of the protein coding sequence, thereby affecting translation repression or activation of target proteins \[[@B20-diseases-04-00021],[@B21-diseases-04-00021]\]. Translation repression can also occur when miRNA targets the coding sequence of the target protein \[[@B22-diseases-04-00021]\]. Alternately, miRNAs can up-regulate the translation of target genes by interacting with regulatory complexes \[[@B23-diseases-04-00021]\]. The function of miRNAs is illustrated in [Figure 2](#diseases-04-00021-f002){ref-type="fig"}.

4. Implication of miRNAs in Cancer {#sec4-diseases-04-00021}
==================================

Recent studies have identified deregulation miRNAs in various tumors ([Table 1](#diseases-04-00021-t001){ref-type="table"}). These miRNAs have been determined to be located in the proximity of the breakpoints, regions of amplification or loss of heterozygocity \[[@B24-diseases-04-00021]\]. Alternately, they can lead to carcinogenesis by altered miRNA expression due to defective miRNA processing, post transcriptional regulation, mutation and epigenetic changes \[[@B11-diseases-04-00021],[@B25-diseases-04-00021],[@B26-diseases-04-00021],[@B27-diseases-04-00021]\]. Their main function in tumorigenesis is to regulate oncogenes or tumor-suppressor genes. These miRNAs that are involved in tumorigenesis are known as oncomirs. They can act as oncogenes by down-regulating genes involved in cell differentiation and apoptosis, or can act as tumor suppressors by down-regulating oncogenes \[[@B28-diseases-04-00021]\]. For example, miR-21 is widely expressed in various types of cancers, and it hinders the activity of tumor-suppressor genes \[[@B29-diseases-04-00021],[@B30-diseases-04-00021]\].

The miR-17-92 cluster (miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a and miR-92-1) also known as oncomiR-1, is aberrantly expressed in various solid tumors \[[@B52-diseases-04-00021]\]. In humans, miR 17-92 is over-expressed in several hematopoietic malignancies and solid tumors \[[@B53-diseases-04-00021]\]. The sequences are highly conserved across species and also within the miR 17-92 family \[[@B54-diseases-04-00021]\]. The expression of miR 17-92 has been studied in animals and human cancer and has been found to show pleiotropic functions \[[@B55-diseases-04-00021],[@B56-diseases-04-00021]\]. Under both normal and malignant transformations, miR 17-92 stimulates proliferation, inhibit differentiation, initiate angiogenesis and promote cell survival.

Members of the let-7 family, mir-15a and mir-16-1, are well-known tumor suppressors that can affect proto-oncogenes like RAS, HMGA2, MYC and IMP-1 \[[@B57-diseases-04-00021],[@B58-diseases-04-00021],[@B59-diseases-04-00021],[@B60-diseases-04-00021]\]. Generally, these miRNAs are down-regulated in most cancers. The oncogenic property of miR 17-92 mainly results in elevated c-myc expression. Other modes of action in carcinogenesis are through the modulation of cell signaling, cell adhesion, hypoxia-related genes and angiogenesis \[[@B61-diseases-04-00021],[@B62-diseases-04-00021],[@B63-diseases-04-00021],[@B64-diseases-04-00021]\].

5. Dietary Phytochemical and Chemoprevention {#sec5-diseases-04-00021}
============================================

Phytochemicals are important constituents of fruits, vegetables and legumes. These naturally occurring bioactive compounds represent a rich source of micronutrients in the human diet \[[@B65-diseases-04-00021]\]. Epidemiological studies have shown that regular consumption of fruits and vegetables reduce the risk of cancer, metabolic syndrome and age-related diseases \[[@B66-diseases-04-00021]\]. Phytochemicals such as isothiocyanates are known to prevent cancer by affecting cellular mechanisms \[[@B67-diseases-04-00021]\]. A majority of these compounds exhibit antioxidant properties and can regulate carcinogenesis by scavenging reactive oxygen species (ROS) and inhibiting other oxidative stress \[[@B68-diseases-04-00021]\]. Other molecular pathways with which phytochemicals inhibit carcinogenesis are by their anti-inflammatory and pro-apoptotic activity \[[@B69-diseases-04-00021]\]. Recent studies have highlighted that the mechanism of chemoprevention also involves modulating miRNAs that regulate cellular pathways associated with inflammation or apoptosis \[[@B70-diseases-04-00021]\].

6. Classification of Polyphenols {#sec6-diseases-04-00021}
================================

Polyphenols represent the most abundant phytochemicals in the human diet. Depending on their chemical structure, they are classified into several groups. Most polyphenols occur in nature as conjugates with sugar or organic acids \[[@B71-diseases-04-00021]\]. The chemical structure consists of a benzene ring attached to one or more hydroxyl groups. They can also form polymers as in the case of flavonoids \[[@B72-diseases-04-00021]\]. Polyphenols and their metabolites can regulate cell functionality by binding to target proteins or by affecting histone modification \[[@B73-diseases-04-00021],[@B74-diseases-04-00021],[@B75-diseases-04-00021]\]. The role of polyphenols in regulating miRNA is not clearly understood. However, recent studies show that polyphenols may be involved in miRNA modulations by multiple mechanisms. Polyphenols can directly bind to miRNAs posttranscriptionally, and they can affect their functionality \[[@B76-diseases-04-00021]\]. They can also bind to mRNAs and proteins, thereby affecting the miRNA biogenesis \[[@B72-diseases-04-00021]\]. The latter involves inhibition of cell signaling by either phosphorylating or dephosphorylating proteins involved in miRNA maturation such as the Dicer complex \[[@B77-diseases-04-00021]\]. Polyphenols can also inhibit transcription factors that bind to the promoter regions of miRNAs \[[@B78-diseases-04-00021]\].

7. Structure of Proanthocyanidins {#sec7-diseases-04-00021}
=================================

Proanthocyanidins are condensed tannins that are the most abundant phytochemicals in nature. Among these, the group that mainly contains (epi)-catechins is known as procyanidins. These procyanidins exist in numerous stereo-chemical isomeric structures ([Figure 3](#diseases-04-00021-f003){ref-type="fig"}). Proanthocyanidins containing (epi)-afzelechin or (epi)-gallocatechin are known as prodelphinidins \[[@B79-diseases-04-00021]\]. They can be broadly differentiated into two subgroups with linkages of catechin or epicatechin at C4-C8 and/or C2-O7 (Type A), or C4-C8 and/or C4-C6 (Type B). They can form complexes with multiple catechins and epicatechins, and with their gallic acid esters to form polymers. The type of polymers are classified as monomers, dimers, trimers, tetramers or oligomers (\>4 polymers) \[[@B80-diseases-04-00021]\]. Proanthocyanidins are found in various foods which include their most common B-type polymers. However, some A-type procyanidins predominantly occur in cranberries, plums, avocados, peanuts and cinnamon \[[@B79-diseases-04-00021]\].

Proanthocyanidins like most other flavonoids, exists in glycosylated forms \[[@B81-diseases-04-00021]\]. The type of glycosylation and its associated sugar moiety greatly influence its absorption \[[@B82-diseases-04-00021]\]. The glycosylated proanthocyanidins are stable during digestion and resist acid hydrolysis \[[@B83-diseases-04-00021]\]. They are catabolized by colonic microflora into metabolites that are absorbed into the circulatory system \[[@B84-diseases-04-00021]\]. The metabolites then reach target tissues and undergo glucuronidation, methylation and sulfation \[[@B85-diseases-04-00021]\]. Some studies also reported the bioavailability of unconjugated B-type procyanidins in plasma reaching a peak concentration within two hours of ingestion \[[@B86-diseases-04-00021],[@B87-diseases-04-00021],[@B88-diseases-04-00021],[@B89-diseases-04-00021],[@B90-diseases-04-00021]\].

8. Proanthocyanidins Influence Regulation of microRNAs *in Vitro* {#sec8-diseases-04-00021}
=================================================================

Research related to the benefits of proanthocyanidins in the regulation of miRNA is relatively new and is being actively investigated. Recent studies have shown that they can modulate miRNAs that play an important role in cancer, glucose and lipid homeostasis \[[@B91-diseases-04-00021],[@B92-diseases-04-00021],[@B93-diseases-04-00021]\]. Current studies establishing the role of procyanidins in miRNAs regulation are presented in the [Table 2](#diseases-04-00021-t002){ref-type="table"}. One study involved cranberry extract treatment to esophaegeal adenocarcinoma (EAC) cell lines and its precursor Barrett's esophagus (BE). This study found that EAC treated with cranberry procyanidin rich extract (CPE) induced miR-410 and miR-520d-5p and reduced miR-202, miR-516a-3p and miR-586 levels \[[@B91-diseases-04-00021]\]. They showed that these five miRNAs are linked to the regulation of target genes that are involved in tumor suppression (p53 and p16), oncogenesis (Rb and Erb8) and inflammation (NFkB). The overall treatment affected 26 genes that play key role in angiogenesis, T-cell activation and apoptosis \[[@B91-diseases-04-00021]\].

Proanthocyanidins extracts from grape seed (GSPE) and cocoa (CPE) differentially expressed miR-30b \*, miR-197, miR-532-3p and miR-1224-3p in HepG2 hepatoma cells \[[@B93-diseases-04-00021]\]. This study suggested that the degree of polymerization, botanical origin and growth conditions could affect miRNA regulation of proanthocyanidins. In another study using GSPE in HepG2 cells, miR-122 and miR-33a levels were reduced \[[@B76-diseases-04-00021]\]. These two miRNAs are known to mediate dyslipedimia and insulin resistance \[[@B94-diseases-04-00021]\]. miR-33a/b regulate cholesterol homeostasis and fatty acid β-oxidation, while miR-122 play a vital role in liver homeostasis \[[@B95-diseases-04-00021],[@B96-diseases-04-00021],[@B97-diseases-04-00021]\]. Because miR-33a/b occurs in the intronic region of the sterol response element proteins (SREBF2 and SREBF1), the authors further investigated if the host gene expression would affect the intronic miRNA levels \[[@B98-diseases-04-00021]\]. Their results showed that host gene SREBP2 expression was unaltered while miRNA expression of miR-33 was modulated.

The authors using ^1^H-NMR spectroscopy reported that EGCG and resveratrol could bind to miRNA and thus influence its target genes. This study directly implicates the role of polyphenols at a posttranscriptional level. This outcome inferred that polyphenols can directly bind to miRNAs and can inhibit their posttranscriptional regulation \[[@B99-diseases-04-00021]\].

9. Animal Model Studies Establish the Role of Proanthocyanidins in miRNA Regulation {#sec9-diseases-04-00021}
===================================================================================

The health-promoting effects of grape proanthocyanidins have been previously studied using animal models \[[@B100-diseases-04-00021],[@B101-diseases-04-00021],[@B102-diseases-04-00021],[@B103-diseases-04-00021],[@B104-diseases-04-00021]\]. Procyanidins are known to exert beneficial effects by regulating lipids homeostasis and reducing atherogenic risk \[[@B96-diseases-04-00021]\]. Studies involving ApoE knockout mice fed with proanthocyanidins for two weeks at a dosage equivalent to human intake of 300 mg/day showed modulation of a total of 55 miRNAs in the livers of Apoe −/− compared to C57BL/6 mice \[[@B105-diseases-04-00021]\]. The highest upregulation was for mmu-miR-133b, a miRNA involved in cell differentiation \[[@B106-diseases-04-00021]\]. Procyanidins exposure at a concentration of 25 mg/kg of bodyweight showed significant downregulation of miR-1249, miR-483, and miR-30c-1 \* and upregulation of miR-3544 in pancreatic islets \[[@B107-diseases-04-00021]\]. Proanthocyanidins are also shown to inhibit AsPC-1 pancreatic cancer cell growth and migration by upregulating let-7a \[[@B108-diseases-04-00021]\].

Grape seed proanthocyanidins (GSP) were also shown to suppress miR-106b in melanoma cells (A375, Hs294t) by arresting G1-phase and increasing p21/WAF1/Cip1 protein levels and affecting its downstream signaling by inhibiting pRb, E2F1 and E2F2 \[[@B109-diseases-04-00021]\]. They also corroborated this finding *in vivo* following A375 cells tumor xenograft in nude mice that showed administration of GSP in the diet reduced tumor growth and suppressed miR-106b expression in the tumors \[[@B109-diseases-04-00021]\].

10. Conclusions {#sec10-diseases-04-00021}
===============

There is a growing amount of evidence that dietary polyphenols are important micronutrients that can play a role in preventing degenerative diseases. Fruits-and-vegetables-based proanthocyanidins are one of the most abundant phytochemicals. They could serve as a tool to benefit human health. Although studies have been undertaken to establish the role of proanthocyanidins in various cancers using *in vitro* and *in vivo* methods, large scale epidemiological data is lacking. Unlike pharmacological drugs, polyphenols are complex compounds and their chemical and biochemical characteristics are dependent on source and cultivar. Clear evidence of their mechanistic function in regulating cellular responses is still unknown. It is hypothecated that polyphenols could modulate miRNA by directly binding it or interacting with key effector proteins involved in miRNA biogenesis. They can also affect miRNA by indirectly regulating its target genes or by modifying host gene expression as some miRNAs are present in intronic regions of the genes. Given the complexity of their structures and their role in affecting multiple cellular pathways simultaneously, attributing their beneficial effects to a distinctive molecular pathway is challenging. Despite these limitations, recent studies have clearly established their role in cancer-prevention. On a similar level, miRNA's role in human epigenetics is just being investigated. There are formidable clinical implications of using miRNAs as an effective chemotherapy. These, combined with advances in nutritional diets designed to address specific disease conditions, will serve to improve the fight against cancer.
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Structure of Type-A and Type-B proanthocyanidins.
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diseases-04-00021-t001_Table 1

###### 

Overview of key microRNAs associated with cancer.

  MicroRNA                   Up- (↑)/Down- (↓) regulation   Cancer type                                       References
  -------------------------- ------------------------------ ------------------------------------------------- -------------------------------------------------------
  miR-21                     ↑                              Lung cancer                                       \[[@B31-diseases-04-00021]\]
  let-7 family               ↓                              Lung cancer cells                                 \[[@B32-diseases-04-00021]\]
  miR-125b, mir-145          ↓                              Breast cancer                                     \[[@B33-diseases-04-00021]\]
  miR-21, mir-155            ↑                                                                                
  miR-27a                    ↑                              Breast cancer                                     \[[@B34-diseases-04-00021],[@B35-diseases-04-00021]\]
  miR-143, mir-145           ↓                              Colorectal cancer                                 \[[@B36-diseases-04-00021]\]
  miR-106a, mir-21           ↑                              Colorectal cancer                                 \[[@B37-diseases-04-00021]\]
  miR-15, mir-16             ↓                              Chronic lymphocytic leukemia (CLL)                \[[@B38-diseases-04-00021]\]
  let-7b, let-7c             ↓                              Acute myeloid leukemia (AML)                      \[[@B39-diseases-04-00021],[@B40-diseases-04-00021]\]
  miR-24                     ↑                                                                                
  miR-29a                    ↑                              B-cell chronic lymphocytic leukemia (CLL)         \[[@B41-diseases-04-00021]\]
  miR-155                    ↑                              \[[@B42-diseases-04-00021]\]                      
  miR-125b                   ↑                              B-cell acute lymphocytic leukemia (ALL)           \[[@B43-diseases-04-00021]\]
  miR-19                     ↑                              T-cell acute lymphocytic leukemia (ALL)           \[[@B44-diseases-04-00021]\]
  miR-21                     ↑                              pre-B malignant lymphoid-like phenotype in mice   \[[@B45-diseases-04-00021]\]
  miR-122                    ↓                              Liver cancer                                      \[[@B46-diseases-04-00021]\]
  miR-221, miR-222, miR-21   ↑                              Hepatocellular carcinoma (HCC)                    \[[@B47-diseases-04-00021]\]
  miR-103, miR-107           ↑                              Pancreatic cancer                                 \[[@B48-diseases-04-00021]\]
  miR-141                    ↑                              Prostate cancer                                   \[[@B49-diseases-04-00021]\]
  miR-221                    ↑                              Ovarian cancer                                    \[[@B50-diseases-04-00021]\]
  miR-21, let-7 family       ↓                                                                                
  miR-17-92 cluster          ↑                              Prostate cancer cells                             \[[@B51-diseases-04-00021]\]

diseases-04-00021-t002_Table 2

###### 

List of miRNAs regulated by proanthocyanidins.

  MicroRNA                                                                                                                                                                                                                                                                                                                                                                                              Up- (↑)/Down- (↓) regulation   Source              Experimental Model                        References
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------ ------------------- ----------------------------------------- ---------------------------------------------------------------------------------
  miR-30b \*                                                                                                                                                                                                                                                                                                                                                                                            ↓                              GSPE ^1^, CPE ^2^   HepG2 cells                               \[[@B93-diseases-04-00021]\]
  miR-1224-3p, miR-197, miR-532-3p                                                                                                                                                                                                                                                                                                                                                                      ↑                                                                                            
  miR-33a, miR-122                                                                                                                                                                                                                                                                                                                                                                                      ↓                              GSPE                Rats, HepG2 cells                         \[[@B76-diseases-04-00021],[@B99-diseases-04-00021],[@B110-diseases-04-00021]\]
  miR-410, miR-520d-5p                                                                                                                                                                                                                                                                                                                                                                                  ↑                              Cranberry-PE ^3^    JHAD1 and OE33 cells                      \[[@B91-diseases-04-00021]\]
  miR-202, miR-516a-3p, miR-586                                                                                                                                                                                                                                                                                                                                                                         ↓                                                                                            
  let-7a                                                                                                                                                                                                                                                                                                                                                                                                ↑                              GSPE                AsPC-1 cells                              \[[@B108-diseases-04-00021]\]
  let-7c-2 \*, miR-125a-3p, miR-146b, miR-190, miR-190b, miR-196a, miR-196b, miR-197, miR-291b-3p, miR-292, miR-294, miR-297a, miR-29a \*, miR-302a, miR-302b, miR-302c, miR-302d, miR-30c-1 \*, miR-335-3p, miR-374 \*, miR-450a-3p, miR-450b-5p, miR-455 \*, miR-464, miR-7b, miR-469, miR-483 \*, miR-487b, miR-505, miR-539, miR-542-3p, miR-551b, miR-669a, miR-676, miR-698, miR-7b \*, miR-881   ↑                              GSPE                Apoe^−/−^ mice                            \[[@B105-diseases-04-00021]\]
  let-7b \*, miR-1, miR-106a, miR-133a, miR-133b, miR-17, miR-181a, miR-191 \*, miR-200c, miR-291b-5p, miR-296-5p, miR-324-5p, miR-374, miR-486, miR-671-5p, miR-801, miR-878-3p, miR-99b                                                                                                                                                                                                               ↓                                                                                            
  miR-3544                                                                                                                                                                                                                                                                                                                                                                                              ↑                              GSPE                Pancreatic islets of Wistar rats          \[[@B107-diseases-04-00021]\]
  miR-1249, miR-483, miR-30c1 \*                                                                                                                                                                                                                                                                                                                                                                        ↓                                                                                            
  miR-106b                                                                                                                                                                                                                                                                                                                                                                                              ↓                              GSPE                A375 cells tumor xenograft in nude mice   \[[@B109-diseases-04-00021]\]

^1^ GSPE: Grape seed proanthocyanidins extract; ^2^ CPE: Cocoa proanthocyanidins extract; ^3^ Cranberry-PE: Cranberry proanthocyanidins extract; \* miRNA originated from the opposite arm of the precursor miRNA
